SI Bone is projected to record more than $200 million in worldwide revenue during fiscal year 2025, according to preliminary ...

SI-BONE reports strong revenue growth and improved financial metrics for Q4 2024 and FY 2024, achieving positive adjusted EBITDA. SI-BONE, Inc. reported strong financial results for the fourth quarter ...

Jim Cramer’s repeated description of SI-BONE (SIBN) as a “great, great speculation,” combined with fresh buy-side analyst ...

SANTA CLARA, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (SIBN), a Silicon Valley-based medical device company dedicated to providing surgical solutions for sacropelvic disorders, today ...

Maheshwari announced, "We're updating our full year revenue guidance to range between $198 million to $200 million. This implies year-over-year growth of approximately 18% to 20% as compared to the ...

Fiscal Year 2025 worldwide revenue of $200.8 to $200.9 million, representing growth of ~20%SANTA CLARA, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in ...

SI-BONE, Inc., a company focused on medical technologies for sacropelvic disorders, announced it will release its financial results for the fourth quarter and full year of 2024 on February 24, 2025, ...

SI-Bone shares rose in after-hours trading as three executives sold stock last week to cover RSU tax obligations.

SANTA CLARA, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving sacropelvic disorders, today reported financial results for the fourth ...

Over 1,400 active U.S. physicians with 300 physicians added in the quarter, representing 27.3% growth CMS FY 2026 proposed hospital inpatient rule for New Technology Add-On Payment (“NTAP”) effective ...

SANTA CLARA, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported ...